Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.

ABSTRACT:

Background

No vaccine is currently available for Lassa fever, a viral hemorrhagic disease that is estimated to cause thousands of deaths each year in western Africa. A replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding a Lassa virus (LASV) glycoprotein complex, rVSVΔG-LASV-GPC, has been developed, but data on its safety and immunogenicity are limited.

Methods

In this phase 1, double-blind trial conducted in the United States and Liberia, we randomly assigned healthy adults (18 to 50 years of age) to receive rVSVΔG-LASV-GPC or placebo intramuscularly. Participants received a single vaccine dose of 2×10⁴ plaque-forming units (PFU), 2×10⁵ PFU, 2×10⁶ PFU, or 2×10⁷ PFU or placebo or received two vacci

SUBMITTER: Malkin E 

PROVIDER: S-EPMC12614316 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature